UK SACT Board annual conference – 28 November 2023

DON’T FORGET TO REGISTER!

UK SACT Board annual conference – 28 November 2023

The UK Systemic Anti-Cancer Therapy (SACT) Board will be hosting its Annual Conference at the Pullman London St Pancras Hotel on Tuesday 28 November 2023. Chaired by Dr Tom Roques, Chair of the UK SACT Board and Vice President, Clinical Oncology at The Royal College of Radiologists, this year’s event will include sessions on SACT capacity in the UK, innovation in SACT practice, a forward look to the next decade in cancer care and digital supportive care.

Registration is just £25 (including VAT). Click here to book your place (booking closes 2 days before the conference) or for more information, please visit the UKSB website.

We look forward to seeing you at what will surely be an exciting, educational and informative day.

Latest News

By UK SACT Board on 9th November 2026

New UK SACT Board National Intrathecal and Intraventricular SACT Guidance

Dear colleagues, We are pleased to share the newly published UK SACT Board National Guidance on the Safe Administration of Systemic Anti-Cancer Therapies via the Intrathecal or Intraventricular Routes. This…

Read article
By BOPA Executive Committee on 9th November 2026

BOPA members flying the flag for cancer pharmacy at ESMO 2026

It was fantastic to see BOPA members representing cancer pharmacy at ESMO Congress 2026 in Madrid, which brought together the global cancer community from 23 to 27 October to share…

Read article
By BOPA Executive Committee on 30th October 2026

Publication of Pharmaceutical Technology and Pharmacology of Parenteral Oncology Drugs

We are delighted to recognise the recent publication of Pharmaceutical Technology and Pharmacology of Parenteral Oncology Drugs, a new book bringing together expertise from oncology pharmacy professionals across the world.…

Read article
By BOPA Executive Committee on 30th October 2026

Acute and Supportive Oncology Clinical Consensus Statement

BOPA welcomes the Acute and Supportive Oncology Clinical Consensus Statement, to which we were pleased to contribute. It will be a benchmark for the sector, bringing direction and consistency as…

Read article